Laureate Biopharma has completed the process development and production of a new potential therapeutic for ischemic stroke with partner ZZ Biotech. The drug, 3K3A-APC, is a form of activated human Protein C with a molecular structure that has been modified to remove the undesirable side effect of bleeding. ZZ Biotech recently began Phase I trials with this material.
 
Kent E. Pryor, Ph.D., chief operating officer of ZZ Biotech, said, "We are pleased to have been able to take a difficult protein out of the research lab and put it into the clinic. Our partnership with Laureate has been integral to turning an idea into a potential new human therapeutic."
 
"This project showcased Laureate's scientific expertise in developing suitable processes for clinical production of challenging proteins," said Michiel E. Ultee, Ph.D., Laureate's chief scientific officer. "We have successfully produced many fusion proteins, IgM antibodies, and other complex recombinant proteins for our clients to evaluate in the clinic."